Provexis PLC
LSE:PXS
Intrinsic Value
Provexis Plc engages in the development and commercialization of Fruitflow, an anti-thrombotic technology. [ Read More ]
The intrinsic value of one PXS stock under the Base Case scenario is 0.03 GBX. Compared to the current market price of 0.65 GBX, Provexis PLC is Overvalued by 96%.
Valuation Backtest
Provexis PLC
Run backtest to discover the historical profit from buying and selling PXS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Provexis PLC
Current Assets | 770.1k |
Cash & Short-Term Investments | 318.8k |
Receivables | 305.4k |
Other Current Assets | 145.9k |
Current Liabilities | 319k |
Accounts Payable | 319k |
Non-Current Liabilities | -531.9k |
Other Non-Current Liabilities | -531.9k |
Earnings Waterfall
Provexis PLC
Revenue
|
598.1k
GBP
|
Cost of Revenue
|
-318.6k
GBP
|
Gross Profit
|
279.4k
GBP
|
Operating Expenses
|
-802.7k
GBP
|
Operating Income
|
-523.3k
GBP
|
Other Expenses
|
26.7k
GBP
|
Net Income
|
-496.6k
GBP
|
Free Cash Flow Analysis
Provexis PLC
What is Free Cash Flow?
PXS Profitability Score
Profitability Due Diligence
Provexis PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Provexis PLC's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PXS Solvency Score
Solvency Due Diligence
Provexis PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Provexis PLC's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PXS Price Targets Summary
Provexis PLC
Shareholder Return
PXS Price
Provexis PLC
Average Annual Return | 28.43% |
Standard Deviation of Annual Returns | 49.63% |
Max Drawdown | -55% |
Market Capitalization | 14.4m GBX |
Shares Outstanding | 2 262 949 888 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Provexis Plc engages in the development and commercialization of Fruitflow, an anti-thrombotic technology. The company is headquartered in Reading, Berkshire and currently employs 2 full-time employees. The company went IPO on 2005-06-24. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The firm also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The firm's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.
Contact
IPO
Employees
Officers
The intrinsic value of one PXS stock under the Base Case scenario is 0.03 GBX.
Compared to the current market price of 0.65 GBX, Provexis PLC is Overvalued by 96%.